Investors & Media

Transformative science, targeted medicines

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-015767.pdf
0001415889-25-015767.rtf
0001415889-25-015767.xls
SC TO-C Written public communication relating to an issuer or third party tender offer View HTML
0001193125-25-134138.pdf
0001193125-25-134138.rtf
0001193125-25-134138.xls
SC TO-C Written public communication relating to an issuer or third party tender offer View HTML
0001193125-25-132712.pdf
0001193125-25-132712.rtf
0001193125-25-132712.xls
8-K Report of unscheduled material events or corporate event View HTML
0001104659-25-055143.pdf
0001104659-25-055143.rtf
0001104659-25-055143.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
SC14D9C Written public communication by the subject company relating to a tender offer by a third party View HTML
0001104659-25-055164.pdf
0001104659-25-055164.rtf
SC14D9C Written public communication by the subject company relating to a tender offer by a third party View HTML
0001104659-25-055435.pdf
0001104659-25-055435.rtf
0001104659-25-055435.xls
SC TO-C Written public communication relating to an issuer or third party tender offer View HTML
0001193125-25-133434.pdf
0001193125-25-133434.rtf
0001193125-25-133434.xls
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-014862.pdf
0001415889-25-014862.rtf
0001415889-25-014862.xls
144 Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing View HTML
0001966249-25-000013.pdf
0001966249-25-000013.rtf
4 Statement of changes in beneficial ownership of securities View HTML
0001415889-25-013941.pdf
0001415889-25-013941.rtf
0001415889-25-013941.xls